Investor Relations

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.